Report Detail

Request for Sample of this report

Pharma & Healthcare Global Metabolic Disorder Therapeutics Market 2024 by Company, Regions, Type and Application, Forecast to 2030

  • RnM3666898
    • |
  • 02 July, 2024
    • |
  • Global
    • |
  • 138 Pages
    • |
  • GIR (Global Info Research)
    • |
  • Pharma & Healthcare

According to our (Global Info Research) latest study, the global Metabolic Disorder Therapeutics market size was valued at USD 48030 million in 2023 and is forecast to a readjusted size of USD 63690 million by 2030 with a CAGR of 4.1% during review period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
The Global Info Research report includes an overview of the development of the Metabolic Disorder Therapeutics industry chain, the market status of Oral (Lysosomal Storage Diseases, Diabetes), Parenteral (Lysosomal Storage Diseases, Diabetes), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Metabolic Disorder Therapeutics.
Regionally, the report analyzes the Metabolic Disorder Therapeutics markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Metabolic Disorder Therapeutics market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Metabolic Disorder Therapeutics market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Metabolic Disorder Therapeutics industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., Lysosomal Storage Diseases, Diabetes).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Metabolic Disorder Therapeutics market.
Regional Analysis: The report involves examining the Metabolic Disorder Therapeutics market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Metabolic Disorder Therapeutics market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Metabolic Disorder Therapeutics:
Company Analysis: Report covers individual Metabolic Disorder Therapeutics players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Metabolic Disorder Therapeutics This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Oral, Parenteral).
Technology Analysis: Report covers specific technologies relevant to Metabolic Disorder Therapeutics. It assesses the current state, advancements, and potential future developments in Metabolic Disorder Therapeutics areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Metabolic Disorder Therapeutics market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Market Segmentation
Metabolic Disorder Therapeutics market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
Lysosomal Storage Diseases
Diabetes
Obesity
Inherited Metabolic Disorders
Hypercholesterolemia
Market segment by Application
Oral
Parenteral
Others
Market segment by players, this report covers
Novo Nordisk A/S
Sanofi S.A.
Boehringer Ingelheim GmbH
Eli Lilly and Company
Merck KgaA
Amgen, Inc.
AstraZeneca PLC
Actelion Pharmaceuticals Ltd.
Shire PLC
AbbVie, Inc.
Biocon Ltd.
BioMarin Pharmaceutical, Inc.
Bristol-Myers Squibb Company
Cipla, Inc.
CymaBay Therapeutics, Inc.
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
South America (Brazil, Argentina and Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Metabolic Disorder Therapeutics product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Metabolic Disorder Therapeutics, with revenue, gross margin and global market share of Metabolic Disorder Therapeutics from 2019 to 2024.
Chapter 3, the Metabolic Disorder Therapeutics competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2019 to 2030.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and Metabolic Disorder Therapeutics market forecast, by regions, type and application, with consumption value, from 2025 to 2030.
Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Metabolic Disorder Therapeutics.
Chapter 13, to describe Metabolic Disorder Therapeutics research findings and conclusion.


1 Market Overview

  • 1.1 Product Overview and Scope of Metabolic Disorder Therapeutics
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Classification of Metabolic Disorder Therapeutics by Type
    • 1.3.1 Overview: Global Metabolic Disorder Therapeutics Market Size by Type: 2019 Versus 2023 Versus 2030
    • 1.3.2 Global Metabolic Disorder Therapeutics Consumption Value Market Share by Type in 2023
    • 1.3.3 Lysosomal Storage Diseases
    • 1.3.4 Diabetes
    • 1.3.5 Obesity
    • 1.3.6 Inherited Metabolic Disorders
    • 1.3.7 Hypercholesterolemia
  • 1.4 Global Metabolic Disorder Therapeutics Market by Application
    • 1.4.1 Overview: Global Metabolic Disorder Therapeutics Market Size by Application: 2019 Versus 2023 Versus 2030
    • 1.4.2 Oral
    • 1.4.3 Parenteral
    • 1.4.4 Others
  • 1.5 Global Metabolic Disorder Therapeutics Market Size & Forecast
  • 1.6 Global Metabolic Disorder Therapeutics Market Size and Forecast by Region
    • 1.6.1 Global Metabolic Disorder Therapeutics Market Size by Region: 2019 VS 2023 VS 2030
    • 1.6.2 Global Metabolic Disorder Therapeutics Market Size by Region, (2019-2030)
    • 1.6.3 North America Metabolic Disorder Therapeutics Market Size and Prospect (2019-2030)
    • 1.6.4 Europe Metabolic Disorder Therapeutics Market Size and Prospect (2019-2030)
    • 1.6.5 Asia-Pacific Metabolic Disorder Therapeutics Market Size and Prospect (2019-2030)
    • 1.6.6 South America Metabolic Disorder Therapeutics Market Size and Prospect (2019-2030)
    • 1.6.7 Middle East and Africa Metabolic Disorder Therapeutics Market Size and Prospect (2019-2030)

2 Company Profiles

  • 2.1 Novo Nordisk A/S
    • 2.1.1 Novo Nordisk A/S Details
    • 2.1.2 Novo Nordisk A/S Major Business
    • 2.1.3 Novo Nordisk A/S Metabolic Disorder Therapeutics Product and Solutions
    • 2.1.4 Novo Nordisk A/S Metabolic Disorder Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
    • 2.1.5 Novo Nordisk A/S Recent Developments and Future Plans
  • 2.2 Sanofi S.A.
    • 2.2.1 Sanofi S.A. Details
    • 2.2.2 Sanofi S.A. Major Business
    • 2.2.3 Sanofi S.A. Metabolic Disorder Therapeutics Product and Solutions
    • 2.2.4 Sanofi S.A. Metabolic Disorder Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
    • 2.2.5 Sanofi S.A. Recent Developments and Future Plans
  • 2.3 Boehringer Ingelheim GmbH
    • 2.3.1 Boehringer Ingelheim GmbH Details
    • 2.3.2 Boehringer Ingelheim GmbH Major Business
    • 2.3.3 Boehringer Ingelheim GmbH Metabolic Disorder Therapeutics Product and Solutions
    • 2.3.4 Boehringer Ingelheim GmbH Metabolic Disorder Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
    • 2.3.5 Boehringer Ingelheim GmbH Recent Developments and Future Plans
  • 2.4 Eli Lilly and Company
    • 2.4.1 Eli Lilly and Company Details
    • 2.4.2 Eli Lilly and Company Major Business
    • 2.4.3 Eli Lilly and Company Metabolic Disorder Therapeutics Product and Solutions
    • 2.4.4 Eli Lilly and Company Metabolic Disorder Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
    • 2.4.5 Eli Lilly and Company Recent Developments and Future Plans
  • 2.5 Merck KgaA
    • 2.5.1 Merck KgaA Details
    • 2.5.2 Merck KgaA Major Business
    • 2.5.3 Merck KgaA Metabolic Disorder Therapeutics Product and Solutions
    • 2.5.4 Merck KgaA Metabolic Disorder Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
    • 2.5.5 Merck KgaA Recent Developments and Future Plans
  • 2.6 Amgen, Inc.
    • 2.6.1 Amgen, Inc. Details
    • 2.6.2 Amgen, Inc. Major Business
    • 2.6.3 Amgen, Inc. Metabolic Disorder Therapeutics Product and Solutions
    • 2.6.4 Amgen, Inc. Metabolic Disorder Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
    • 2.6.5 Amgen, Inc. Recent Developments and Future Plans
  • 2.7 AstraZeneca PLC
    • 2.7.1 AstraZeneca PLC Details
    • 2.7.2 AstraZeneca PLC Major Business
    • 2.7.3 AstraZeneca PLC Metabolic Disorder Therapeutics Product and Solutions
    • 2.7.4 AstraZeneca PLC Metabolic Disorder Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
    • 2.7.5 AstraZeneca PLC Recent Developments and Future Plans
  • 2.8 Actelion Pharmaceuticals Ltd.
    • 2.8.1 Actelion Pharmaceuticals Ltd. Details
    • 2.8.2 Actelion Pharmaceuticals Ltd. Major Business
    • 2.8.3 Actelion Pharmaceuticals Ltd. Metabolic Disorder Therapeutics Product and Solutions
    • 2.8.4 Actelion Pharmaceuticals Ltd. Metabolic Disorder Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
    • 2.8.5 Actelion Pharmaceuticals Ltd. Recent Developments and Future Plans
  • 2.9 Shire PLC
    • 2.9.1 Shire PLC Details
    • 2.9.2 Shire PLC Major Business
    • 2.9.3 Shire PLC Metabolic Disorder Therapeutics Product and Solutions
    • 2.9.4 Shire PLC Metabolic Disorder Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
    • 2.9.5 Shire PLC Recent Developments and Future Plans
  • 2.10 AbbVie, Inc.
    • 2.10.1 AbbVie, Inc. Details
    • 2.10.2 AbbVie, Inc. Major Business
    • 2.10.3 AbbVie, Inc. Metabolic Disorder Therapeutics Product and Solutions
    • 2.10.4 AbbVie, Inc. Metabolic Disorder Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
    • 2.10.5 AbbVie, Inc. Recent Developments and Future Plans
  • 2.11 Biocon Ltd.
    • 2.11.1 Biocon Ltd. Details
    • 2.11.2 Biocon Ltd. Major Business
    • 2.11.3 Biocon Ltd. Metabolic Disorder Therapeutics Product and Solutions
    • 2.11.4 Biocon Ltd. Metabolic Disorder Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
    • 2.11.5 Biocon Ltd. Recent Developments and Future Plans
  • 2.12 BioMarin Pharmaceutical, Inc.
    • 2.12.1 BioMarin Pharmaceutical, Inc. Details
    • 2.12.2 BioMarin Pharmaceutical, Inc. Major Business
    • 2.12.3 BioMarin Pharmaceutical, Inc. Metabolic Disorder Therapeutics Product and Solutions
    • 2.12.4 BioMarin Pharmaceutical, Inc. Metabolic Disorder Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
    • 2.12.5 BioMarin Pharmaceutical, Inc. Recent Developments and Future Plans
  • 2.13 Bristol-Myers Squibb Company
    • 2.13.1 Bristol-Myers Squibb Company Details
    • 2.13.2 Bristol-Myers Squibb Company Major Business
    • 2.13.3 Bristol-Myers Squibb Company Metabolic Disorder Therapeutics Product and Solutions
    • 2.13.4 Bristol-Myers Squibb Company Metabolic Disorder Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
    • 2.13.5 Bristol-Myers Squibb Company Recent Developments and Future Plans
  • 2.14 Cipla, Inc.
    • 2.14.1 Cipla, Inc. Details
    • 2.14.2 Cipla, Inc. Major Business
    • 2.14.3 Cipla, Inc. Metabolic Disorder Therapeutics Product and Solutions
    • 2.14.4 Cipla, Inc. Metabolic Disorder Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
    • 2.14.5 Cipla, Inc. Recent Developments and Future Plans
  • 2.15 CymaBay Therapeutics, Inc.
    • 2.15.1 CymaBay Therapeutics, Inc. Details
    • 2.15.2 CymaBay Therapeutics, Inc. Major Business
    • 2.15.3 CymaBay Therapeutics, Inc. Metabolic Disorder Therapeutics Product and Solutions
    • 2.15.4 CymaBay Therapeutics, Inc. Metabolic Disorder Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
    • 2.15.5 CymaBay Therapeutics, Inc. Recent Developments and Future Plans

3 Market Competition, by Players

  • 3.1 Global Metabolic Disorder Therapeutics Revenue and Share by Players (2019-2024)
  • 3.2 Market Share Analysis (2023)
    • 3.2.1 Market Share of Metabolic Disorder Therapeutics by Company Revenue
    • 3.2.2 Top 3 Metabolic Disorder Therapeutics Players Market Share in 2023
    • 3.2.3 Top 6 Metabolic Disorder Therapeutics Players Market Share in 2023
  • 3.3 Metabolic Disorder Therapeutics Market: Overall Company Footprint Analysis
    • 3.3.1 Metabolic Disorder Therapeutics Market: Region Footprint
    • 3.3.2 Metabolic Disorder Therapeutics Market: Company Product Type Footprint
    • 3.3.3 Metabolic Disorder Therapeutics Market: Company Product Application Footprint
  • 3.4 New Market Entrants and Barriers to Market Entry
  • 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

  • 4.1 Global Metabolic Disorder Therapeutics Consumption Value and Market Share by Type (2019-2024)
  • 4.2 Global Metabolic Disorder Therapeutics Market Forecast by Type (2025-2030)

5 Market Size Segment by Application

  • 5.1 Global Metabolic Disorder Therapeutics Consumption Value Market Share by Application (2019-2024)
  • 5.2 Global Metabolic Disorder Therapeutics Market Forecast by Application (2025-2030)

6 North America

  • 6.1 North America Metabolic Disorder Therapeutics Consumption Value by Type (2019-2030)
  • 6.2 North America Metabolic Disorder Therapeutics Consumption Value by Application (2019-2030)
  • 6.3 North America Metabolic Disorder Therapeutics Market Size by Country
    • 6.3.1 North America Metabolic Disorder Therapeutics Consumption Value by Country (2019-2030)
    • 6.3.2 United States Metabolic Disorder Therapeutics Market Size and Forecast (2019-2030)
    • 6.3.3 Canada Metabolic Disorder Therapeutics Market Size and Forecast (2019-2030)
    • 6.3.4 Mexico Metabolic Disorder Therapeutics Market Size and Forecast (2019-2030)

7 Europe

  • 7.1 Europe Metabolic Disorder Therapeutics Consumption Value by Type (2019-2030)
  • 7.2 Europe Metabolic Disorder Therapeutics Consumption Value by Application (2019-2030)
  • 7.3 Europe Metabolic Disorder Therapeutics Market Size by Country
    • 7.3.1 Europe Metabolic Disorder Therapeutics Consumption Value by Country (2019-2030)
    • 7.3.2 Germany Metabolic Disorder Therapeutics Market Size and Forecast (2019-2030)
    • 7.3.3 France Metabolic Disorder Therapeutics Market Size and Forecast (2019-2030)
    • 7.3.4 United Kingdom Metabolic Disorder Therapeutics Market Size and Forecast (2019-2030)
    • 7.3.5 Russia Metabolic Disorder Therapeutics Market Size and Forecast (2019-2030)
    • 7.3.6 Italy Metabolic Disorder Therapeutics Market Size and Forecast (2019-2030)

8 Asia-Pacific

  • 8.1 Asia-Pacific Metabolic Disorder Therapeutics Consumption Value by Type (2019-2030)
  • 8.2 Asia-Pacific Metabolic Disorder Therapeutics Consumption Value by Application (2019-2030)
  • 8.3 Asia-Pacific Metabolic Disorder Therapeutics Market Size by Region
    • 8.3.1 Asia-Pacific Metabolic Disorder Therapeutics Consumption Value by Region (2019-2030)
    • 8.3.2 China Metabolic Disorder Therapeutics Market Size and Forecast (2019-2030)
    • 8.3.3 Japan Metabolic Disorder Therapeutics Market Size and Forecast (2019-2030)
    • 8.3.4 South Korea Metabolic Disorder Therapeutics Market Size and Forecast (2019-2030)
    • 8.3.5 India Metabolic Disorder Therapeutics Market Size and Forecast (2019-2030)
    • 8.3.6 Southeast Asia Metabolic Disorder Therapeutics Market Size and Forecast (2019-2030)
    • 8.3.7 Australia Metabolic Disorder Therapeutics Market Size and Forecast (2019-2030)

9 South America

  • 9.1 South America Metabolic Disorder Therapeutics Consumption Value by Type (2019-2030)
  • 9.2 South America Metabolic Disorder Therapeutics Consumption Value by Application (2019-2030)
  • 9.3 South America Metabolic Disorder Therapeutics Market Size by Country
    • 9.3.1 South America Metabolic Disorder Therapeutics Consumption Value by Country (2019-2030)
    • 9.3.2 Brazil Metabolic Disorder Therapeutics Market Size and Forecast (2019-2030)
    • 9.3.3 Argentina Metabolic Disorder Therapeutics Market Size and Forecast (2019-2030)

10 Middle East & Africa

  • 10.1 Middle East & Africa Metabolic Disorder Therapeutics Consumption Value by Type (2019-2030)
  • 10.2 Middle East & Africa Metabolic Disorder Therapeutics Consumption Value by Application (2019-2030)
  • 10.3 Middle East & Africa Metabolic Disorder Therapeutics Market Size by Country
    • 10.3.1 Middle East & Africa Metabolic Disorder Therapeutics Consumption Value by Country (2019-2030)
    • 10.3.2 Turkey Metabolic Disorder Therapeutics Market Size and Forecast (2019-2030)
    • 10.3.3 Saudi Arabia Metabolic Disorder Therapeutics Market Size and Forecast (2019-2030)
    • 10.3.4 UAE Metabolic Disorder Therapeutics Market Size and Forecast (2019-2030)

11 Market Dynamics

  • 11.1 Metabolic Disorder Therapeutics Market Drivers
  • 11.2 Metabolic Disorder Therapeutics Market Restraints
  • 11.3 Metabolic Disorder Therapeutics Trends Analysis
  • 11.4 Porters Five Forces Analysis
    • 11.4.1 Threat of New Entrants
    • 11.4.2 Bargaining Power of Suppliers
    • 11.4.3 Bargaining Power of Buyers
    • 11.4.4 Threat of Substitutes
    • 11.4.5 Competitive Rivalry

12 Industry Chain Analysis

  • 12.1 Metabolic Disorder Therapeutics Industry Chain
  • 12.2 Metabolic Disorder Therapeutics Upstream Analysis
  • 12.3 Metabolic Disorder Therapeutics Midstream Analysis
  • 12.4 Metabolic Disorder Therapeutics Downstream Analysis

13 Research Findings and Conclusion

    14 Appendix

    • 14.1 Methodology
    • 14.2 Research Process and Data Source

    Summary:
    Get latest Market Research Reports on Metabolic Disorder Therapeutics. Industry analysis & Market Report on Metabolic Disorder Therapeutics is a syndicated market report, published as Global Metabolic Disorder Therapeutics Market 2024 by Company, Regions, Type and Application, Forecast to 2030. It is complete Research Study and Industry Analysis of Metabolic Disorder Therapeutics market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

    Last updated on

    REPORT YOU MIGHT BE INTERESTED

    Purchase this Report

    		$3,480.00
    		$5,220.00
    		$6,960.00
    		2,686.56
    		4,029.84
    		5,373.12
    		3,198.12
    		4,797.18
    		6,396.24
    		529,203.60
    		793,805.40
    		1,058,407.20
    		292,876.80
    		439,315.20
    		585,753.60
    Credit card Logo
    Sample Question Discount Download PDF

    Related Reports

    Reason to Buy

    • Trusted By Leaders

      Top executives from leading companies purchase research reports from us. 

    • Shop With Confidence

      We assist you with all the pre-sales enquiries related to any report so that you can buy with confidence.

    • Customer Centric

      Need assistance related to your research requirements? We are just a phone call or an email away.

    • Personalized Solutions

      Our experienced research specialists are here to help you locate the right reports for your need.

    • Secure Checkout

      Shop without being worried about safety & security of your transactions.
      •

    Request for Sample of this report

    Reports and Markets

    mcafree

    Contact Us

    +1-352-353-0818 (US)

    info@reportsandmarkets.com

    Support

    EMAIL US

    Newsletter

    KEEP UP TO DATE ON ALL THE LATEST REPORTS


    maxmind_logo